Matthias Englbrecht1, Rieke Alten2, Martin Aringer3, Christoph G Baerwald4, Harald Burkhardt5, Nancy Eby6, Gerhard Fliedner7, Bettina Gauger8, Ulf Henkemeier9, Michael W Hofmann10, Stefan Kleinert11, Christian Kneitz12, Klaus Krueger13, Christoph Pohl2, Anne-Eve Roske8, Georg Schett1, Marc Schmalzing14, Anne-Kathrin Tausche3, Hans Peter Tony14, Joerg Wendler15. 1. University of Erlangen-Nuremberg, Erlangen, Germany. 2. University Medicine Berlin, Berlin, Germany. 3. University Clinical Center Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. 4. University of Leipzig, Leipzig, Germany. 5. Johann Wolfgang Goethe University Frankfurt am Main, Frankfurt, Germany. 6. AMS Advanced Medical Services GmbH, Mannheim, Germany. 7. Rheumatologische Schwerpunktpraxis, Stuttgart, Germany. 8. Roche Pharma AG, Grenzach-Wyhlen, Germany. 9. University Hospital Frankfurt am Main Goethe-University, Frankfurt, Germany. 10. Chugai Pharma Europe Ltd., Frankfurt, Germany. 11. University Hospital of Wuerzburg, Wuerzburg, Germany. 12. Klinikum Suedstadt Rostock, Klinik für Innere Medizin II, Rostock, Germany. 13. Praxiszentrum St. Bonifatius, Munich, Germany. 14. University of Wuerzburg, Wuerzberg, Germany. 15. Rheumatologische Schwerpunktpraxis, Erlangen, Germany.
Abstract
OBJECTIVE: To validate standard self-report questionnaires for depression screening in patients with rheumatoid arthritis (RA) and compare these measures to one another and to the Montgomery-Åsberg Depression Rating Scale (MADRS), a standardized structured interview. METHODS: In 9 clinical centers across Germany, depressive symptomatology was assessed in 262 adult RA patients at baseline (T0) and at 12 ± 2 weeks followup (T1) using the World Health Organization 5-Item Well-Being Index (WHO-5), the Patient Health Questionnaire (PHQ-9), and the Beck Depression Inventory II (BDI-II). The construct validity of these depression questionnaires (using convergent and discriminant validity) was evaluated using Spearman's correlations at both time points. The test-retest reliability of the questionnaires was evaluated in RA patients who had not undergone a psychotherapeutic intervention or received antidepressants between T0 and T1. The sensitivity and the specificity of the questionnaires were calculated using the results of the MADRS, a structured interview, as the gold standard. RESULTS: According to Spearman's correlation coefficients, all questionnaires met convergent validity criteria (ρ > |0.50|), with the BDI-II performing best, while correlations with age and disease activity for all questionnaires met the criteria for discriminant validity (ρ < |0.50|). The only questionnaire to meet the predefined retest reliability criterion (ρ ≥ 0.70) was the BDI-II (rs = 0.77), which also achieved the best results for both sensitivity and specificity (>80%) when using the MADRS as the gold standard. CONCLUSION: The BDI-II best met the predefined criteria, and the PHQ-9 met most of the validity criteria, with lower sensitivity and specificity.
OBJECTIVE: To validate standard self-report questionnaires for depression screening in patients with rheumatoid arthritis (RA) and compare these measures to one another and to the Montgomery-Åsberg Depression Rating Scale (MADRS), a standardized structured interview. METHODS: In 9 clinical centers across Germany, depressive symptomatology was assessed in 262 adult RApatients at baseline (T0) and at 12 ± 2 weeks followup (T1) using the World Health Organization 5-Item Well-Being Index (WHO-5), the Patient Health Questionnaire (PHQ-9), and the Beck Depression Inventory II (BDI-II). The construct validity of these depression questionnaires (using convergent and discriminant validity) was evaluated using Spearman's correlations at both time points. The test-retest reliability of the questionnaires was evaluated in RApatients who had not undergone a psychotherapeutic intervention or received antidepressants between T0 and T1. The sensitivity and the specificity of the questionnaires were calculated using the results of the MADRS, a structured interview, as the gold standard. RESULTS: According to Spearman's correlation coefficients, all questionnaires met convergent validity criteria (ρ > |0.50|), with the BDI-II performing best, while correlations with age and disease activity for all questionnaires met the criteria for discriminant validity (ρ < |0.50|). The only questionnaire to meet the predefined retest reliability criterion (ρ ≥ 0.70) was the BDI-II (rs = 0.77), which also achieved the best results for both sensitivity and specificity (>80%) when using the MADRS as the gold standard. CONCLUSION: The BDI-II best met the predefined criteria, and the PHQ-9 met most of the validity criteria, with lower sensitivity and specificity.
Authors: Ingrid V Bassett; Sharon M Coleman; Janet Giddy; Laura M Bogart; Christine E Chaisson; Douglas Ross; Moses J E Flash; Tessa Govender; Rochelle P Walensky; Kenneth A Freedberg; Elena Losina Journal: J Acquir Immune Defic Syndr Date: 2017-04-01 Impact factor: 3.731
Authors: Matthias Englbrecht; Rieke Alten; Martin Aringer; Christoph G Baerwald; Harald Burkhardt; Nancy Eby; Jan-Paul Flacke; Gerhard Fliedner; Ulf Henkemeier; Michael W Hofmann; Stefan Kleinert; Christian Kneitz; Klaus Krüger; Christoph Pohl; Georg Schett; Marc Schmalzing; Anne-Kathrin Tausche; Hans-Peter Tony; Jörg Wendler Journal: PLoS One Date: 2019-05-28 Impact factor: 3.240
Authors: Carol A Hitchon; Lixia Zhang; Christine A Peschken; Lisa M Lix; Lesley A Graff; John D Fisk; Scott B Patten; James Bolton; Jitender Sareen; Renée El-Gabalawy; James Marriott; Charles N Bernstein; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2020-07-08 Impact factor: 4.794